Curcumin delivered through bovine serum albumin/polysaccharides multilayered microcapsules
Source abstract
Abstract
The aim of the paper is to obtain and characterize k-carrageenan–chitosan dual hydrogel multilayers shell BSA gel microcapsules, as a carrier for curcumin, and as a possible antitumoral agent in biological studies. We used the CaCO 3 template to synthesize non-toxic CaCO 3 /BSA particles as microtemplates by coprecipitating a CaCl 2 solution that contains dissolved BSA, with an equimolar Na 2 CO 3 solution. The microcapsules shell is assembled through a layer-by-layer deposition technique of calcium cross-linked k-carrageenan hydrogel alternating with polyelectrolite complex hydrogel formed via electrostatic interactions between k-carrageenan and chitosan. After the removal of CaCO 3 through Ca 2+ complexation with EDTA, and by a slightly treatment with HCl diluted solution, the BSA core is turned into a BSA gel through a thermal treatment. The BSA gel microcapsules were then loaded with curcumin, through a diffusion process from curcumin ethanolic solution. All the synthesized particles and microcapsules were stucturally characterized by: Fourier Transform Infrared Spectroscopy, UV–Vis Spectrometry, X-ray diffraction, thermal analysis, fluorescence spectroscopy, fluorescence optical microscopy, confocal laser scanning microscopy and scanning electron microscopy. The behavior of curcumin loaded microcapsules in media of different pH (SGF, SIF and PBS) was studied in order to reveal the kinetics and the release profile of curcumin. The in vitro evaluation of the antitumoral activity of encapsulated curcumin microcapsules on HeLa cell line and the primary culture of mesenchymal stem cells is the main reason of the microcapsules synthesis as BSA-based vehicle meant to enhance the biodisponibility of curcumin, whose anti-tumor, anti-oxidant and anti-inflammatory properties are well known.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Educational and Social Studies · Italian Social Issues and Migration · Educational Practices and Policies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Technical University of Cluj-Napoca, Cluj-Napoca, Romania
The Oncology Institute Prof. Dr. I. Chiricuta, Cluj-Napoca, Romania
“Raluca Ripan” Institute for Research in Chemistry, Cluj-Napoca, Romania
National Institute for Research and Development of Isotopic and Molecular Technologies, Cluj-Napoca, Romania
University of Agricultural Science and Veterinary Medicine, Cluj-Napoca, Romania
References (42)
Show source-provided references
1. 10.1016/j.carbpol.2013.07.01710.1016/j.carbpol.2013.07.017 ↗
2. 10.1016/j.biocel.2008.06.01010.1016/j.biocel.2008.06.010 ↗
3. 10.1016/j.canlet.2008.03.00910.1016/j.canlet.2008.03.009 ↗
4. 10.1016/j.gene.2014.06.00610.1016/j.gene.2014.06.006 ↗
5. 10.1016/j.ijpharm.2014.01.00910.1016/j.ijpharm.2014.01.009 ↗
6. 10.1016/j.biomaterials.2010.08.11210.1016/j.biomaterials.2010.08.112 ↗
7. 10.1016/j.ejps.2013.08.03610.1016/j.ejps.2013.08.036 ↗
8. 10.1016/j.carbpol.2013.06.01310.1016/j.carbpol.2013.06.013 ↗
9. 10.1016/j.jcis.2010.05.02210.1016/j.jcis.2010.05.022 ↗
10. 10.1016/j.ejmech.2014.06.06910.1016/j.ejmech.2014.06.069 ↗
11. 10.1016/j.jcis.2011.04.00610.1016/j.jcis.2011.04.006 ↗
12. 10.1016/j.colsurfb.2010.10.02110.1016/j.colsurfb.2010.10.021 ↗
13. 10.1016/j.irbm.2010.02.00110.1016/j.irbm.2010.02.001 ↗
14. 10.1016/j.reactfunctpolym.2012.04.00310.1016/j.reactfunctpolym.2012.04.003 ↗
15. 10.1016/S0939-6411(00)00090-410.1016/S0939-6411(00)00090-4 ↗
16. Kean T · 2009 · 327
17. 10.1016/S0169-409X(01)00231-910.1016/S0169-409X(01)00231-9 ↗
18. 10.1016/j.progpolymsci.2011.02.00110.1016/j.progpolymsci.2011.02.001 ↗
19. 10.1016/j.ijpharm.2005.11.04810.1016/j.ijpharm.2005.11.048 ↗
20. 10.1016/j.carbpol.2009.01.02010.1016/j.carbpol.2009.01.020 ↗
21. 10.1016/j.jallcom.2011.12.02610.1016/j.jallcom.2011.12.026 ↗
22. 10.1016/j.carbpol.2013.10.04910.1016/j.carbpol.2013.10.049 ↗
23. Liu J, Zhan X, Wan J, et al. Review for carrageenan-based pharmaceutical biomaterials: Favourable physical features versus adverse biological effects. C arbohydr Polym 2015; 121: 27–36.10.1016/j.carbpol.2014.11.063 ↗
24. 10.1016/j.ijpharm.2012.10.00810.1016/j.ijpharm.2012.10.008 ↗
25. 10.1016/j.jconrel.2008.05.01010.1016/j.jconrel.2008.05.010 ↗
26. 10.1016/j.ultsonch.2006.11.00410.1016/j.ultsonch.2006.11.004 ↗
27. 10.1016/j.actbio.2012.12.02410.1016/j.actbio.2012.12.024 ↗
28. Matsumura Y · Cancer Res · 1986 · 46 · 6387
29. 10.1023/A:101580711975310.1023/A:1015807119753 ↗
30. 10.1021/nn205099c10.1021/nn205099c ↗
31. 10.1002/(SICI)1521-3773(19980904)37:16<2201::AID-ANIE2201>3.0.CO;2-E10.1002/(SICI)1521-3773(19980904)37:16<2201::AID-ANIE2201>3.0.CO;2-E ↗
32. 10.1039/B600460C10.1039/B600460C ↗
33. 10.1021/bm049669e10.1021/bm049669e ↗
34. 10.1126/science.277.5330.123210.1126/science.277.5330.1232 ↗
35. 10.1016/S0927-7757(98)00213-110.1016/S0927-7757(98)00213-1 ↗
36. 10.1021/nl902697j10.1021/nl902697j ↗
37. 10.1016/j.carbpol.2010.08.00810.1016/j.carbpol.2010.08.008 ↗
38. 10.1063/1.471775310.1063/1.4717753 ↗
39. Govindaraj P · Mater ChemPhys · 2014 · 147 · 934
40. Sharma R · Indian J Pharm Educ · 2011 · 55 · 25
41. 10.1016/j.carbpol.2010.06.03710.1016/j.carbpol.2010.06.037 ↗
42. 10.1016/0040-6031(94)02087-510.1016/0040-6031(94)02087-5 ↗